Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EBMT 2020 | Post-transplant bendamustine for GvHD prophylaxis in refractory acute leukemia

Ivan Moiseev • 30 Aug 2020
EBMT 2020
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia Bendamustine Busulfan Cyclophosphamide Fludarabine

Ivan Moiseev, MD, PhD, First Saint Petersburg State Medical University, Saint Petersburg, Russia, outlines the use of post-transplant bendamustine for GvHD prophylaxis as evaluated in a dose-escalation study in patients with refractory acute leukemias (NCT02799147). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ivan Moiseev

Significance of MRD negativity in Ph-negative ALL 1:01
Significance of MRD negativity in Ph-negative ALL
Ivan Moiseev • 1 Sep 2020
GO-FLAG: bridge therapy to allo-SCT in R/R AML 0:53
GO-FLAG: bridge therapy to allo-SCT in R/R AML
Ivan Moiseev • 30 Aug 2020
Impact of post-transplant TKIs on long-term outcomes of allo-HSCT in ALL 1:27
Impact of post-transplant TKIs on long-term outcomes of allo-HSCT in ALL
Ivan Moiseev • 1 Sep 2020
Mutational profiles of MDS patients undergoing allo-HSCT 1:29
Mutational profiles of MDS patients undergoing allo-HSCT
Ivan Moiseev • 30 Aug 2020

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals